BioVie (BIVI) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with all directors, key executives, independent accountant, and outside counsel present virtually.
Polls opened for voting on all matters to be presented.
Corporate governance
Record date for voting set as September 22, 2025, with 7,535,080 shares outstanding, each entitled to one vote.
Quorum established with over 45% of shares represented virtually or by proxy.
Inspector of Election appointed and sworn in to oversee voting and tally results.
Board and executive committee updates
Six directors nominated and elected for a one-year term: Jim Lang, Cuong Do, Michael Sherman, Sigmund Rojich, Amy Chappell, and Kameel Farag.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioVie
- Phase II data for Parkinson's and long COVID expected in 2024; BIV201 phase III planning underway.BIVI
Status update4 Mar 2026 - Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist.BIVI
Q2 20266 Feb 2026 - All proposals, including director elections and plan amendments, passed with strong approval.BIVI
AGM 202415 Jan 2026 - Key clinical trials advance with strong cash runway and major data readouts expected by mid-2026.BIVI
Investor Update29 Dec 2025 - Shareholders will vote on director elections, auditor ratification, say-on-pay, and a major equity plan increase.BIVI
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and expanding the equity plan.BIVI
Proxy Filing2 Dec 2025 - Virtual annual meeting to vote on directors, auditor, pay, and expanded equity plan.BIVI
Proxy Filing2 Dec 2025 - Supplement details updated executive and director compensation, equity awards, and related party transactions.BIVI
Proxy Filing2 Dec 2025 - Shareholders to vote on a reverse stock split and adjournment authority to support Nasdaq compliance.BIVI
Proxy Filing2 Dec 2025